Yamanouchi Seeks Larger U.S. Presence Through Fujisawa Merger

The $7.8 bil. deal would ramp up the companies' sales efforts to primary care physicians. In the U.S., Fujisawa details only to the specialty care audience, while Yamanouchi relies on out-licensing agreements.